Obesity and Endometrial Cancer: Mechanism and How to Deal with?
DOI:
https://doi.org/10.55175/cdk.v48i6.85Keywords:
Endometrial cancer, mechanism, obesity, obese womenAbstract
Obesity is strongly associated with development of endometrial cancer more than any other cancer type. The relationship between obesity and endometrial cancer risk is combination of inflammation, insulin resistance, and increased bioavailability of estrogen. Obesity can increase risk to develop endometrial cancer as exogenous estrogen has impact for tumorigenesis. The best method to reduce the risk of endometrial cancer in obese women is through progesterone medication and lifestyle intervention.
Obesitas erat kaitannya dengan terjadinya kanker endometrium lebih dari jenis kanker lainnya. Hubungan antara obesitas dan risiko kanker endometrium adalah kombinasi antara inflamasi, resistensi insulin, dan peningkatan bioavailabilitas estrogen. Obesitas dapat meningkatkan risiko terjadinya kanker endometrium karena estrogen eksogen berdampak pada tumorigenesis. Metode terbaik untuk mengurangi risiko kanker endometrium pada wanita yang obese adalah melalui pengobatan progesteron dan intervensi gaya hidup.
Downloads
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Int J Gynecol Cancer [Internet]. 2016 Jan 1 [cited 2020 Aug 13];26(1). Available from: https://ijgc.bmj.com/content/26/1/2
Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women study: Cohort study. BMJ. 2007;335(7630):1134.
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34(35):4225–30.
Teoh SL, Das S. Tumour biology of obesity-related cancers: Understanding the molecular concept for better diagnosis and treatment. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016;37(11):14363–80.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet Lond Engl. 2008;371(9612):569–78.
McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2008;17(1):73–9.
Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484–98.
Allott EH, Hursting SD. Obesity and cancer: Mechanistic insights from transdisciplinary studies. Endocr Relat Cancer. 2015;22(6):365-86.
Blakemore J, Naftolin F. Aromatase: Contributions to physiology and disease in women and men. Physiol Bethesda Md. 2016;31(4):258–69.
O’Connor KA, Ferrell RJ, Brindle E, Shofer J, Holman DJ, Miller RC, et al. Total and unopposed estrogen exposure across stages of the transition to menopause. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2009;18(3):828–36.
Simó R, Sáez-López C, Barbosa-Desongles A, Hernández C, Selva DM. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab TEM. 2015;26(7):376–83.
Thomas C, Gustafsson JÅ. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11(8):597–608.
Cavalieri EL, Rogan EG. Depurinating estrogen-DNA adducts, generators of cancer initiation: Their minimization leads to cancer prevention. Clin Transl Med. 2016;5(1):12.
Batte BAL, Bruegl AS, Daniels MS, Ring KL, Dempsey KM, Djordjevic B, et al. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for lynch syndrome. Gynecol Oncol. 2014;134(2):319–25.
Mills AM, Longacre TA. Lynch syndrome: Female genital tract cancer diagnosis and screening. Surg Pathol Clin. 2016;9(2):201–14.
Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: Opportunities for prevention. Am J Obstet Gynecol. 2011;205(6):518–25.
Simó R, Barbosa-Desongles A, Sáez-Lopez C, Lecube A, Hernandez C, Selva DM. Molecular mechanism of TNFα-induced down-regulation of SHBG expression. Mol Endocrinol Baltim Md. 2012;26(3):438–46.
Nagle CM, Olsen CM, Ibiebele TI, Spurdle AB, Webb PM, Astralian National Endometrial Cancer Study Group, et al. Glycemic index, glycemic load and endometrial cancer risk: Results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. Eur J Nutr. 2013;52(2):705–15.
George SM, Ballard R, Shikany JM, Crane TE, Neuhouser ML. A prospective analysis of diet quality and endometrial cancer among 84,415 postmenopausal women in the Women’s Health Initiative. Ann Epidemiol. 2015;25(10):788–93.
Chandran U, Bandera EV, Williams-King MG, Sima C, Bayuga S, Pulick K, et al. Adherence to the dietary guidelines for Americans and endometrial cancer risk. cancer causes control CCC. 2010;21(11):1895–904.
Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: A systematic review. Maturitas. 2016;91:25–35.
Endometrial cancer and oral contraceptives: An individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16(9):1061–70.
Bokhari AA, Lee LR, Raboteau D, Turbov J, Rodriguez IV, Pike JW, et al. Progesterone potentiates the growth inhibitory effects of calcitriol in endometrial cancer via suppression of CYP24A1. Oncotarget. 2016;7(47):77576–90.
Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Ou Shu X, Weiderpass E, et al. Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer J Int Cancer. 2015;136(5):E410–22.
Lauretta R, Lanzolla G, Vici P, Mariani L, Moretti C, Appetecchia M. Insulin-sensitizers, polycystic ovary syndrome and gynaecological cancer risk. Int J Endocrinol. 2016;2016:8671762.
Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 2014;132(2):438–42.
Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of endometrial cancer: A case-control analysis. Gynecol Oncol. 2013;129(3):565–9.
Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;(1):CD005552.
Kitson S, Ryan N, MacKintosh ML, Edmondson R, Duffy JM, Crosbie EJ. Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database Syst Rev. 2018;2:CD012513.
Anveden Å, Taube M, Peltonen M, Jacobson P, Andersson-Assarsson JC, Sjöholm K, et al. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish obese subjects study. Gynecol Oncol. 2017;145(2):224–9.
Bruno DS, Berger NA. Impact of bariatric surgery on cancer risk reduction. Ann Transl Med [Internet]. 2020 Mar [cited 2020 Aug 13];8(Suppl 1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154324/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
